Evidence mapPaperPMID 39790031Full record

SynthesisPharmaceutical biology2025

Research progress of Chinese medicinal monomers in the process of melanoma occurrence.

Yan Shang, Hailong Zhao

Abstract readSystematic Review
In one paragraph

Synthesis in Pharmaceutical biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yan ShangDepartment of Pathophysiology, Zunyi Medical University, Zunyi, China.
Hailong ZhaoDepartment of Pathophysiology, Zunyi Medical University, Zunyi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextMelanoma's aggressiveness and resistance to radiotherapy highlight an urgent need for innovative treatments. Traditional Chinese medicine (TCM) offers a unique approach through its 'four natures' theory-cold, cool, warm, and hot.

objectiveThis review aims to explore the potential of TCM's 'four natures' herbal monomers in melanoma treatment, providing an alternative to conventional therapies. MATERIALS &

methodsA systematic literature review was conducted by accessing various databases, including Baidu Scholar, PubMed, Science Citation Index Expanded (SCIE), and China National Knowledge Infrastructure (CNKI), to synthesize the most recent findings on traditional Chinese medicine monomers. Furthermore, this review elucidated the mechanisms underlying their role in melanoma retention.

resultsTCM's multi-component, multi-target approach has shown promise in addressing melanoma's complexity, with specific monomers demonstrating the ability to modulate tumor behavior. DISCUSSION AND

conclusionsThe 'four natures' theory in TCM presents a novel perspective for melanoma treatment, warranting further investigation into its clinical applications and potential integration with modern oncology.

Indexed as

Drugs, Chinese HerbalMedicine, Chinese TraditionalMelanomaAnimalsAntineoplastic Agents, PhytogenicHumansSkin NeoplasmsAntineoplastic Agents, PhytogenicDrugs, Chinese HerbalChinese medicinal monomersherbal antitumor activityMelanomamelanomagenesis inhibitiontraditional Chinese medication (TCM)

Identifiers

PMID39790031
PMCPMC11727062

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.